This is my theory on CYDY and why it is where it is. It is

New Post Public Reply Private Reply Replies (3) Message Board
zagnut
906
This is my theory on CYDY and why it is where it is. It is not uncommon to see this in big stakes pharma. Taken from poster whom I follow from when we both had IMMU and am invested in SAVA now. Same crap, different company. The problem is it is business as usual and it’s all about money, not saving lives. Contrary to his position, I tend to believe BP is involved in our situation. Excerpt below:

have resisted the idea that BP is involved, but at this point I am inclined to agree with Springer that the perp is the negotiating partner, who of course has enlisted a hedge fund to execute the plan. Knock down the stock price artificially as if the public has lost all confidence, meanwhile discrediting the company, the science, the mechanism of action relentlessly on all fronts. On something potentially worth 200+ billion in market cap, you might easily save a billion dollars or more. If this were simply a short play, they would have covered long ago and switched to the long side.

SavaDx seems to be a negotiating point. The company went from freely promoting SavaDx to stating recently that they were currently not pursuing it. And now this! Another 180° flip. (See below, from the company Website) Back in play. Sure smells like licensing negotiations.

This stock is being obliterated. Obviously, as evidenced by Schwab, no more shares are available to short. In fact naked shorts, which surely dwarf legally borrowed shorts, are probably maxed out, because naked is the preferred method-- no borrowing cost. Someone estimated there to be 500 million naked shorts against this stock. If that is true, a market maket is definitely involved. They have legal privilege.

Springer makes a compelling case that Point 72 is behind this. My theory is that they recruited not only a market maker, but also Citadel with whom they are as thick as thieves. I have already presented Citadel's activity in SAVA in the last quarter from their 13F.

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

NIDS Aims Global with CES 2027, Boosts Sensor Supply

Updated Category News Views 189

Pushing Boundaries at CES 2027 Kicking into high gear, NIDS Co., Ltd. is eyeing the CES 2027 stage like it's their personal gold rush. Already a heavyweight in environmental sensors, the company is all set to seize fresh international opportunities and expand their B2B supply footprint worldwide. Already Turning Heads Founded back in 2000, NIDS ain't new to the sensor...

Continue Reading
NABEP's Strategic Push: 41 Rigs to Bolster Output

Updated Category News Views 208

On The Ground: NABEP's Expanding Venezuelan Presence Think of oil production as a high-stakes poker game where each drill and rig is a well-placed bet. North American Blue Energy Partners (NABEP) is going all in on Venezuela, boosting their rig fleet and pushing production capacity to new heights. Set your sights on November when NABEP's in-country fleet will hit 41 rigs...

Continue Reading
BAIC FOTON Eyes Africa for Bold Expansion Moves

Updated Category News Views 133

Pushing the Pedal to the Metal in Africa So here's the thing. When a company like BAIC FOTON sets its sights on Africa, you best believe they're not just twiddling their thumbs. Coming off a strong streak in the commercial vehicle game—topping China's sales for 21 years and exports for 15—their ambitions are now married to a keen interest in Africa's burgeoning...

Continue Reading
Millrose Properties Faces Legal Storm: Investors Alerted

Updated Category News Views 187

Millrose Properties: A Storm's Brewing Whoa, step back and take a wide-eyed look at Millrose Properties—there’s a storm brewin’ and it’s a doozy! Right now, they’re up against one mighty class action lawsuit, and investors who’ve been hit for over $100k better circle December 8, 2026, on their calendars if they fancy a shot at lead plaintiff glory. We’re...

Continue Reading
Langford Chosen for Navy Mutual's 2026 Bolles Award

Updated Category News Views 225

Awarding a Military Financial Educator There's something profoundly rewarding when hard work and dedication get their due recognition. That's precisely what's happened for Lacey Langford, who’s just been awarded the Lieutenant Timothy Dix Bolles Excellency in Education Award by the Navy Mutual Aid Association, or simply Navy Mutual. This isn’t just some...

Continue Reading
Zhimeng Biopharma Hits Key Milestone in ALS Drug Trial

Updated Category News Views 156

Pivotal Point for Zhimeng's ALS Efforts Folks, get this—Zhimeng Biopharma's rolling out the big guns here with a significant step forward in their ALS treatment quest. This company just wrapped up patient enrollment for their next-gen ALS drug, CB03-154. We're talking about 255 patients now on board for a Phase 2/3 trial. The ground's shaking a bit because this...

Continue Reading
DKS Lawsuit Deadline: Investors Must Act by Nov 3, 2026

Updated Category News Views 78

Clock's Ticking for DICK'S Investors If you've got money tied up in DICK'S Sporting Goods—bought between September 8, 2025, and August 24, 2026—listen up. There's a class action lawsuit aiming to recover some of what might've slipped through your fingers. Come November 3, 2026, the door slams shut on your chance to get involved. What's the Beef? Apparently, DICK'S had...

Continue Reading
ScienceOra Unveils AI Catalyst Design at Tencent Summit

Updated Category News Views 110

AI in Material Science: Beyond Buzzwords There's a lot of talk out there about AI changing the world, but it's always a different tune when it's put under a microscope. At the 2026 Tencent Global Digital Ecosystem Summit, ScienceOra and Wenge AI showcased an AI-assisted workflow for designing hydrogen-production catalysts. This isn't your average AI cheerleading session,...

Continue Reading
Fluence Energy Faces Class Action: Investors Beware

Updated Category News Views 116

Storm Clouds Over Fluence Energy I'll tell you, I ain't surprised when companies face the music for dressing up their books. Fluence Energy, Inc. (NASDAQ: FLNC)—those wallopers are now caught in a legal maelstrom with a securities fraud class action lawsuit hanging over their heads. It's hard to feel sorry for 'em when the writing's on the wall. Allegations and...

Continue Reading
Wulcea Pioneers Safety in Smart Heated Apparel

Updated Category News Views 71

Tech Behind the Warmth and Safety You ever turn on a heated jacket and wonder if it'll keep you safe as much as warm? That's the scene with Wulcea, a brand diving headfirst into the smart heated clothing market. People are waking up to what’s inside these technological coats, not just how they feel on a frosty walk. It’s the kind of scenario where safety meets...

Continue Reading

Top 5 Most Recently Viewed Articles

Gentoo Media Announces Shareholders Meeting Details

Updated Category News Views 164

Gentoo Media’s Upcoming Annual Meeting of Shareholders The Annual Meeting of Shareholders for Gentoo Media Inc. is set to take place at KG10, Kungsgatan 8, 111 43 in Stockholm, Sweden, on an upcoming Tuesday. This event is pivotal as it gathers shareholders to discuss the company’s progress and future directions. What to Expect at the Meeting At the meeting,...

Continue Reading
ConnectOne Bancorp's Q3 Earnings: Merger Insights and Outlook

Updated Category News Views 242

ConnectOne Bancorp's Strategic Endeavors in the Third Quarter In a recent earnings call, ConnectOne Bancorp (NASDAQ: CNOB) revealed a merger with First of Long Island Corporation, aimed at significantly boosting the bank's market footprint and credit quality. This merger, anticipated to finalize in the first half of 2025, positions ConnectOne with assets exceeding $14...

Continue Reading
Voyager Therapeutics to Showcase Innovations at Conferences

Updated Category News Views 87

Voyager Therapeutics to Showcase at Upcoming Investor Conferences Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology firm focused on advancing neurogenetic therapies, has announced its participation in several upcoming investor conferences. These events aim to highlight the company's innovative research and development efforts in treating neurological diseases....

Continue Reading
Why Invest in Venture Debt: High Returns, Lower Risk

Updated Category Investing Views 819

The Benefits of Venture Debt as a Strategic Investment For investors seeking attractive risk-adjusted returns beyond traditional stock and bond markets, venture debt has emerged as an appealing private credit option with compelling characteristics. This alternative asset class provides companies with capital to fuel expansion while offering lenders enticing yields and...

Continue Reading
C3 AI and McKinsey Unite to Transform Enterprise AI Solutions

Updated Category News Views 383

C3 AI and McKinsey Unite to Transform Enterprise AI Solutions C3 AI (NYSE: AI), recognized as a leading force in the Enterprise AI software industry, has announced a significant alliance with McKinsey & Company, a distinguished global management consulting firm. This partnership is set to pave the way for accelerating Enterprise AI transformations that can resonate across...

Continue Reading